In Brief This Week: Roche NimbleGen; Life Technologies; PerkinElmer; Luminex; CLC bio; Diffinity Genomics; Vela Diagnostics; Bayer CropScience | GenomeWeb

NEW YORK (GenomeWeb News) – Roche will shutter its NimbleGen microarray business, and will phase out array production and services by the end of the year. At the same time, the firm will continue to provide target enrichment products for use with next-generation sequencing, a spokesperson told GenomeWeb Daily News sister publication BioArray News this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.